HCC
BMRN icon

Hirtle Callaghan & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Hirtle Callaghan & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-550
Closed -$34K – 567
2014
Q2 		$34K Sell
550
-200
-27% -$12.1K ﹤0.01% 404
2014
Q1 		$51K Hold
750
– – 0.01% 348
2013
Q4 		$53K Buy
+750
New +$50.9K 0.01% 326

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Hirtle Callaghan & Co's BMRN Position: Q3 2014 in Review

Hirtle Callaghan & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2014, closing a stake of 550 shares — an estimated $34K sold.

Hirtle Callaghan & Co first reported a position in BMRN in Q4 2013 and held it in 3 quarters. The position peaked at $53K in Q4 2013. 316 funds tracked by Wall St. Rank hold BMRN as of Q3 2014.

  • Hirtle Callaghan & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 550 BioMarin Pharmaceuticals shares in Q3 2014, an estimated $34K.
  • Hirtle Callaghan & Co first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Hirtle Callaghan & Co's BioMarin Pharmaceuticals position peaked at $53K in Q4 2013.
  • 316 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2014.

Based on Hirtle Callaghan & Co's 13F filing for Q3 2014, filed 29 Oct 2014.